Vnitr Lek 2017, 63(5):361-364 | DOI: 10.36290/vnl.2017.072

Stanovisko panelu expertů odborných společností k použití tikagreloru v léčbě akutních koronárních syndromů u nemocných se sníženou renální funkcí

Panel expertů odborných společností (Česká internistická společnost ČLS JEP, Česká kardiologická společnost, Česká nefrologická společnost a Česká společnost klinické biochemie ČLS JEP)

Received: June 6, 2017; Published: May 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Panel expertů odborných společností (Česká internistická společnost ČLS JEP Česká kardiologická společnost Česká nefrologická společnost a Česká společnost klinické biochemie ČLS JEP). Stanovisko panelu expertů odborných společností k použití tikagreloru v léčbě akutních koronárních syndromů u nemocných se sníženou renální funkcí. Vnitr Lek. 2017;63(5):361-364. doi: 10.36290/vnl.2017.072.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Anavekar NS, McMurray JJ, Velazquez EJ et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351(13): 1285-1295. Dostupné z DOI: <http://doi:10.1056/NEJMoa041365>. Go to original source... Go to PubMed...
    2. Best PJ, Lennon R, Ting HH et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002; 39(7): 1113-1119. Dostupné z DOI: <http://doi:10.1016/S0735-1097(02)01745-X>. Go to original source... Go to PubMed...
    3. Ezekowitz J, McAlister FA, Humphries KH et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol 2004; 44(8): 1587-1592. Dostupné z DOI: <http://doi:10.1016/j.jacc.2004.06.072>. Go to original source... Go to PubMed...
    4. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(2 Suppl 1): S1-S266. Dostupné z WWW: <http://www.ajkd.org/article/S0272-6386(02)70089-9/pdf>.
    5. Levey AS, Eckardt KU, Tsukamoto Y et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes. Kidney Int 2005; 67(6): 2089-2100. Dostupné z DOI: <http://doi:10.1111/j.1523-1755.2005.00365.x>. Go to original source... Go to PubMed...
    6. James S, Akerblom A, Cannon CP et al. Comparison of ticagrelor, the first reversible oral p2y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the Platelet Inhibition and Patient Outcomes (PLATO) trial. Am Heart J 2009; 157(4): 599-605. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ahj.2009.01.003>. Go to original source... Go to PubMed...
    7. James S, Budaj A, Aylward P et al. Ticagrelor versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function Results Ffrom the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation 2010; 122(11): 1056-1067. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.109.933796>. Go to original source... Go to PubMed...
    8. Best PJ, Steinhubl SR, Berger PB et al. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events during Observation (CREDO) trial. Am Heart J 2008; 155(4): 687-693. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ahj.2007.10.046>. Go to original source... Go to PubMed...
    9. Keltai M, Tonelli M, Mann JF et al. Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. Eur J Cardiovasc Prev Rehabil 2007; 14(2): 312-318. Dostupné z DOI: <http://doi:10.1097/01.hjr.0000220582.19516.a6>. Go to original source... Go to PubMed...
    10. Státní ústav pro kontrolu léčiv. Jednání výboru pro humánní léčivé přípravky (CMHP) 14.-17. prosince 2015. Informace dostupné z WWW: <http://www.sukl.cz/modules/medication/search.php?data%5Bsearch_for%5D=brilique&data%5Bcode%5D=&data%5Batc_group%5D=&data%5Bmaterial%5D=&data%5Bpath%5D=&data%5Breg%5D=&data%5Bradio%5D=none&data%5Brc%5D=&data%5Bchbox%5D%5B%5D=braill-yes&data%5Bchbox%5D%5B%5D=braill-no&data%5Bchbox%5D%5B%5D=braill-def&data%5Bwith_adv%5D=0&search=Vyhledat&data%5Blisting%5D=20>NEBO <http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/12/news_detailhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/12/news_detail_002445.jsp∣=WC0b01ac058004d5c1_002445.jsp∣=WC0b01ac058004d5c1>.
    11. Zima T, Racek J, Tesař V et al. Doporučení k diagnostice chronického onemocnění ledvin (odhad glomerulární filtrace a vyšetřování proteinurie) České nefrologické společnosti ČLS JEP a České společnosti klinické biochemie ČLS JEP. Klin Biochem Metab 2014; 22(3): 138-152. Dostupné z WWW: <http://www.cskb.cz/res/file/KBM-pdf/2014/2014-3/KBM_3_2014_Dop-ledviny-139.pdf>.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.